%0 Journal Article
%T Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial - Fertility and Sterility
%A Cristina L. Benetti-Pinto
%A Deborah Margatho
%A Kleber Cursino
%A Luis Bahamondes
%A Nelsilene Carvalho
%J Fertility and Sterility
%D 2018
%R https://doi.org/10.1016/j.fertnstert.2018.07.003
%X To assess the efficacy of an etonogestrel (ENG)-releasing contraceptive implant or the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) in the control of endometriosis-associated pelvic pain. Noninferiority randomized clinical trial in which women with endometriosis were assigned to use an ENG implant (experimental treatment) or an LNG-IUS (active comparator). Monthly follow-up visits were conducted up to 6 months. University teaching hospital. One hundred three women, with endometriosis-associated chronic pelvic pain, dysmenorrhea, or both for more than 6 months. In cases of deep endometriosis, vaginal ultrasonography and magnetic resonance imaging were used as additional diagnostic tools. The ENG implant or the LNG-IUS were inserted within the first 5 days of the menstrual cycle. Daily scores of noncyclic pelvic pain and dysmenorrhea were evaluated using a daily visual analogue scale. Health-related quality of life was evaluated using the Endometriosis Health Profile-30 questionnaire at baseline and up to 6 months. Bleeding patterns were assessed daily from a menstrual calendar. Both contraceptives improved significantly the mean visual analogue scale endometriosis-associated pelvic pain and dysmenorrhea, without significant differences between treatment group profiles. Health-related quality of life improved significantly in all domains of the core and modular segments of the Endometriosis Health Profile-30 questionnaire, with no difference between both treatment groups. The most common bleeding patterns at 180 days of follow-up were amenorrhea and infrequent bleeding and infrequent bleeding and spotting among ENG implant and LNG-IUS users, respectively. In this noninferiority study both contraceptives improved significantly pelvic pain, dysmenorrhea, and health-related quality of life in endometriosis. Clinicaltrials.gov under number NCT02480647. Control del dolor asociado a endometriosis con implante anticonceptivo liberador de etonogestrel y sistema intrauterino liberador de levonorgestrel de 52 mg: ensayo cl¨ªnico aleatorizado Evaluar la eficacia de un implante anticonceptivo de liberaci¨®n de etonogestrel (ENG) o el sistema intrauterino de liberaci¨®n de levonorgestrel (LNG-IUS) de 52 mg en el control del dolor p¨¦lvico asociado a endometriosis. Ensayo cl¨ªnico aleatorizado de no-inferioridad en el que se asign¨® a mujeres con endometriosis el uso de un implante ENG (tratamiento experimental) o un LNG-IUS (comparador activo). Se realizaron visitas mensuales de seguimiento hasta los 6 meses. Hospital Universitario. Ciento tres mujeres con
%U https://www.fertstert.org/article/S0015-0282(18)30568-5/fulltext